Display options
Cite
Lavanderos MA, Cayún JP, Roco Á, et al. Association Study Among Candidate Genetic Polymorphisms and Chemotherapy-Related Severe Toxicity in Testicular Cancer Patients. Front Pharmacol. 2019;10:206doi: 10.3389/fphar.2019.00206.
Lavanderos, M. A., Cayún, J. P., Roco, �. �., Sandoval, C., Cerpa, L., Rubilar, J. C., Cerro, R., Molina-Mellico, S., Celedón, C., Cerda, B., García-Martín, E., Agúndez, J. A. G., Acevedo, C., Peña, K., Cáceres, D. D., Varela, N. M., & Quiñones, L. A. (2019). Association Study Among Candidate Genetic Polymorphisms and Chemotherapy-Related Severe Toxicity in Testicular Cancer Patients. Frontiers in pharmacology, 10206. https://doi.org/10.3389/fphar.2019.00206
Lavanderos, María A, et al. "Association Study Among Candidate Genetic Polymorphisms and Chemotherapy-Related Severe Toxicity in Testicular Cancer Patients." Frontiers in pharmacology vol. 10 (2019): 206. doi: https://doi.org/10.3389/fphar.2019.00206
Lavanderos MA, Cayún JP, Roco Á, Sandoval C, Cerpa L, Rubilar JC, Cerro R, Molina-Mellico S, Celedón C, Cerda B, García-Martín E, Agúndez JAG, Acevedo C, Peña K, Cáceres DD, Varela NM, Quiñones LA. Association Study Among Candidate Genetic Polymorphisms and Chemotherapy-Related Severe Toxicity in Testicular Cancer Patients. Front Pharmacol. 2019 Mar 08;10:206. doi: 10.3389/fphar.2019.00206. eCollection 2019. PMID: 30914949; PMCID: PMC6421934.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2019 Mar 08;10:206. doi: 10.3389/fphar.2019.00206. eCollection 2019.

Association Study Among Candidate Genetic Polymorphisms and Chemotherapy-Related Severe Toxicity in Testicular Cancer Patients.

Frontiers in pharmacology

María A Lavanderos, Juan P Cayún, Ángela Roco, Christopher Sandoval, Leslie Cerpa, Juan C Rubilar, Roberto Cerro, Sebastián Molina-Mellico, Cesar Celedón, Berta Cerda, Elena García-Martín, José A G Agúndez, Cristián Acevedo, Karina Peña, Dante D Cáceres, Nelson M Varela, Luis A Quiñones

Affiliations

  1. Laboratory of Chemical Carcinogenesis and Pharmacogenetics, Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile.
  2. Servicio Metropolitano de Salud Occidente, Santiago, Chile.
  3. Instituto Nacional del Cáncer, Santiago, Chile.
  4. Institute of Molecular Pathology Biomarkers, ARADyAL, University of Extremadura, Cáceres, Spain.
  5. Clinical Hospital University of Chile, Santiago, Chile.
  6. Department of Oncology, Hospital San Juan de Dios, Santiago, Chile.
  7. Instituto de Salud Poblacional, Facultad de Medicina, Universidad de Chile, Santiago, Chile.

PMID: 30914949 PMCID: PMC6421934 DOI: 10.3389/fphar.2019.00206

Abstract

Testicular cancer is one of the most commonly occurring malignant tumors in young men with fourfold higher rate of incidence and threefold higher mortality rates in Chile than the average global rates. Surgery is the initial line of treatment for testicular cancers, and is generally followed by chemotherapy, usually with combinations of bleomycin, etoposide, and cisplatin (BEP). However, the adverse effects of chemotherapy vary significantly among individuals; therefore, the present study explored the association of functionally significant allelic variations in genes related to the pharmacokinetics/pharmacodynamics of BEP and DNA repair enzymes with chemotherapy-induced toxicity in BEP-treated testicular cancer patients. We prospectively recruited 119 patients diagnosed with testicular cancer from 2010 to 2017. Genetic polymorphisms were analyzed using PCR and/or qPCR with

Keywords: ADRs; pharmacogenetics; polymorphisms; testicular cancer; toxicity

References

  1. Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4680-5 - PubMed
  2. Cancer Lett. 1999 Jul 1;141(1-2):167-71 - PubMed
  3. Genes Dev. 2001 Jan 1;15(1):15-23 - PubMed
  4. Cancer Res. 2001 Oct 1;61(19):7130-5 - PubMed
  5. AAPS PharmSci. 2000;2(1):E4 - PubMed
  6. Pharmacogenomics J. 2002;2(1):43-7 - PubMed
  7. Mutagenesis. 2002 Nov;17(6):463-9 - PubMed
  8. Curr Drug Metab. 2004 Jun;5(3):211-24 - PubMed
  9. BMJ. 2004 Jul 3;329(7456):15-9 - PubMed
  10. Drug Metab Dispos. 2004 Sep;32(9):993-1000 - PubMed
  11. Am J Epidemiol. 2004 Nov 1;160(9):825-41 - PubMed
  12. DNA Repair (Amst). 2005 Sep 28;4(10):1068-74 - PubMed
  13. J Clin Oncol. 2006 Apr 20;24(12):1883-91 - PubMed
  14. Int Urol Nephrol. 2006;38(3-4):621-4 - PubMed
  15. Nat Rev Cancer. 2007 Aug;7(8):573-84 - PubMed
  16. Mol Diagn Ther. 2007;11(6):361-80 - PubMed
  17. J Clin Oncol. 2008 Apr 10;26(11):1817-23 - PubMed
  18. Neuro Oncol. 2009 Jun;11(3):292-300 - PubMed
  19. CA Cancer J Clin. 2009 Jan-Feb;59(1):42-55 - PubMed
  20. Rev Med Chil. 2008 Oct;136(10):1327-35 - PubMed
  21. Curr Med Chem. 2009;16(7):854-66 - PubMed
  22. Arh Hig Rada Toksikol. 2009 Jun;60(2):217-42 - PubMed
  23. Pharmacogenomics J. 2010 Feb;10(1):62-9 - PubMed
  24. Pharmacogenomics J. 2010 Feb;10(1):54-61 - PubMed
  25. Cancer Genet Cytogenet. 2010 Apr 1;198(1):40-6 - PubMed
  26. Biochem Biophys Res Commun. 2010 May 21;396(1):90-4 - PubMed
  27. J Transl Med. 2011 Mar 23;9:31 - PubMed
  28. J Popul Ther Clin Pharmacol. 2011;18:e134-51 - PubMed
  29. Mol Pharmacol. 2011 Jul;80(1):136-46 - PubMed
  30. Cancer Chemother Pharmacol. 2012 Jan;69(1):25-33 - PubMed
  31. Oncologist. 2011;16(6):820-34 - PubMed
  32. Pharmacogenomics. 2011 Dec;12(12):1641-52 - PubMed
  33. Malays J Med Sci. 2007 Jan;14(1):10-7 - PubMed
  34. Front Genet. 2012 Nov 02;3:229 - PubMed
  35. Cancer. 1985 Nov 15;56(10):2411-5 - PubMed
  36. Cancer. 1987 May 1;59(9):1582-5 - PubMed
  37. Front Genet. 2014 Nov 14;5:391 - PubMed
  38. Cell J. 2015 Summer;17(2):187-92 - PubMed
  39. Pharmacol Ther. 2016 Mar;159:35-55 - PubMed
  40. PLoS One. 2016 Jun 21;11(6):e0157651 - PubMed
  41. Dent Hypotheses. 2016 Jul-Sep;7(3):73-80 - PubMed
  42. Int J Oncol. 2017 Jan;50(1):223-231 - PubMed
  43. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2017 Feb 20;39(1):150-155 - PubMed
  44. Pharmacotherapy. 2017 Aug;37(8):956-972 - PubMed
  45. Postepy Hig Med Dosw (Online). 2017 Jun 19;71(0):541-550 - PubMed
  46. Rev Med Chil. 2017 Apr;145(4):483-500 - PubMed
  47. Asian Pac J Cancer Prev. ;18(7):1815-1819 - PubMed
  48. Biochim Biophys Acta Gen Subj. 2019 Jan;1863(1):52-60 - PubMed
  49. Int J Clin Oncol. 2019 Mar;24(3):256-261 - PubMed
  50. J Biol Chem. 1995 Sep 29;270(39):22657-60 - PubMed
  51. Trends Biochem Sci. 1995 Oct;20(10):435-9 - PubMed
  52. Cancer. 1996 Aug 1;78(3):416-21 - PubMed
  53. Br J Clin Pharmacol. 1995 Dec;40(6):523-30 - PubMed
  54. Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13176-81 - PubMed

Publication Types